Eli Lilly and Co (LLY)

78.17
0.19 0.24
NYSE : Health Care
Prev Close 77.99
Open 77.99
Day Low/High 77.80 / 78.28
52 Wk Low/High 64.18 / 86.72
Volume 704.14K
Avg Volume 3.96M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 84.94B
EPS 2.60
P/E Ratio 37.19
Div & Yield 2.08 (2.70%)

Latest News

Eli Lilly Stock Faces Uncertainty, Bernstein Says

Eli Lilly Stock Faces Uncertainty, Bernstein Says

Although Berstein analyst Tim Anderson has an 'Outperfrom' rating and $88 price target on Eli Lilly, he warned clients in a note today that investors may be overlooking risks.

Actress Angela Bassett Joins For Your SweetHeart™ To Urge People With Diabetes To Know Their Heart Disease Risk -- In Honor Of Her Mom

Actress Angela Bassett Joins For Your SweetHeart™ To Urge People With Diabetes To Know Their Heart Disease Risk -- In Honor Of Her Mom

Bassett encourages people with type 2 diabetes and their loved ones to take and share the Heart You Quiz to learn more about the No. 1 killer of people with this condition

Here Are Some of Congress' Favorite Stocks

Here Are Some of Congress' Favorite Stocks

While hard at work in Washington, a handful of members of Congress have also been busy trading stocks.

Leigh Ann Pusey Joins Lilly As Senior Vice President Of Corporate Affairs And Communications

Leigh Ann Pusey Joins Lilly As Senior Vice President Of Corporate Affairs And Communications

Insurance industry veteran will lead Lilly public affairs and lobbying efforts

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

Eli Lilly Stock Downgraded at Argus

Eli Lilly Stock Downgraded at Argus

Eli Lilly stock is trading near its 52-week high and is 'well above peer-average multiples,' Argus said.

Nasdaq Tops 6,000 in Busy Day of Milestones for Wall Street

Nasdaq Tops 6,000 in Busy Day of Milestones for Wall Street

Another big rally made for a day of milestones: the Dow and S&P 500 enjoyed their best back-to-back gains of the year, while the Nasdaq scored a new record.

Novartis, Amgen Divvy Global Marketing of New Migraine Drug

Novartis, Amgen Divvy Global Marketing of New Migraine Drug

Estimates for erenumab annual sales run as high as $2.3 billion.

Stocks Hold at Highs as Dow, S&P 500 Enjoy Best Two-Day Stretch of 2017

Stocks Hold at Highs as Dow, S&P 500 Enjoy Best Two-Day Stretch of 2017

Better-than-expected earnings from industry leaders including Caterpillar and McDonald's push the Dow to log triple-digit gains for the second day in a row, its best two-day stretch of the year.

Eli Lilly Stock Falls on Continued Arthritis Drug Approval Delay

Eli Lilly Stock Falls on Continued Arthritis Drug Approval Delay

Eli Lilly's EPS for the 2017 first quarter was slightly better than analysts expected.

Caterpillar Hauls Dow Sharply Higher, Nasdaq Tops 6,000 for First Time

Caterpillar Hauls Dow Sharply Higher, Nasdaq Tops 6,000 for First Time

A stream of positive earnings reports keep stocks on the rise on Tuesday with the Dow Jones Industrial Average logging triple-digit gains for the second day in a row.

Stock Futures See More Gains on a Stream of Positive Earnings

Stock Futures See More Gains on a Stream of Positive Earnings

Stock futures move higher on Tuesday, extending gains seen a day earlier, after a series of positive earnings results from the likes of DuPont, Novartis, and Rite Aid.

Market Recon: We Need a Deal to Keep the Federal Government Humming

Market Recon: We Need a Deal to Keep the Federal Government Humming

Some kind of spending deal will have to be in place by Saturday in order to avoid the mayhem.

European Stocks Edge Higher Ahead of Active U.S. Earnings Slate

European Stocks Edge Higher Ahead of Active U.S. Earnings Slate

European stocks extended gains Tuesday as global markets continued to rally in the wake of Emmanuel Macron's victory in Sunday's presidential elections in France and improving corporate earnings.

European Stocks Called Higher as Global 'French Election' Rally Extends Gains

European Stocks Called Higher as Global 'French Election' Rally Extends Gains

European stocks are expected to extend gains Tuesday as global markets continue to rally in the wake of Emmanuel Macron's victory in Sunday's presidential elections in France.

Sweet Sounds of Numbers; Have Faith: Jim Cramer's View

Sweet Sounds of Numbers; Have Faith: Jim Cramer's View

Cramer shares his views on the preponderance of evidence, and suggests having faith in interational strength.

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.

Turnarounds are Tenuous Things: Cramer's 'Mad Money' Recap (Wednesday 04/19/17)

Turnarounds are Tenuous Things: Cramer's 'Mad Money' Recap (Wednesday 04/19/17)

IBM's busted turnaround and difficult transition story shaved more than 50 points off the Dow, says Jim Cramer.

Wall Street Ends Its Losing Streak As Corporate Earnings Take Focus

Wall Street Ends Its Losing Streak As Corporate Earnings Take Focus

Stocks close in positive territory Monday ahead of a big week for U.S. corporate earnings.

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.

Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results

Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results

JNJ's diabetes and oncology franchises will also be key when the New Brunswick, N.J.-based healthcare giant reports first-quarter numbers Tuesday morning.